Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer

We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. Patients with advanced-stage NSCLC treated wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ramalingam, Suresh S., Owonikoko, Taofeek K., Behera, Madhusmita, Subramanian, Janakiraman, Saba, Nabil F., Kono, Scott A., Gal, Anthony A., Sica, Gabriel, Harvey, R. Donald, Chen, Zhengjia, Klass, Carmen M., Shin, Dong M., Fu, Haian, Sun, Shi-yong R., Govindan, Ramaswamy, Khuri, Fadlo R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126230/
https://ncbi.nlm.nih.gov/pubmed/23407561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318282709c
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados